Research & Literature

Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers.

van den Brand M, Mathijssen JJ, Garcia-Garcia M, et al.

Haematologica 2015; (100(9)):e358-60 doi:10.3324/haematol.2014.120956.

Optimizing therapy for nodal marginal zone lymphoma.

Thieblemont C, Molina T, Davi F

Blood 2016; (127(17)):2064-71 doi:10.1182/blood-2015-12-624296.

A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.

Ozawa MG, Bhaduri A, Chisholm KM, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(10)):1212-20 doi:10.1038/modpathol.2016.102.

Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.

Barzenje DA, Holte H, Fosså A, et al.

Leukemia & lymphoma 2017; (58(3)):623-632 doi:10.1080/10428194.2016.1204653.

Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

Starr AG, Caimi PF, Fu P, et al.

British journal of haematology 2016; (175(2)):275-280 doi:10.1111/bjh.14228.

Nodal marginal zone mutational signature.

Piris MA

Blood 2016; (128(10)):1315-6 doi:10.1182/blood-2016-07-724963.

Pediatric-type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma: Recent Clinical, Morphologic, Immunophenotypic, and Genetic Insights.

Koo M, Ohgami RS

Advances in anatomic pathology 2017; (24(3)):128-135 doi:10.1097/PAP.0000000000000144.

Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.

Tadmor T, Polliack A

Best practice & research. Clinical haematology 2017; (30(1-2)):92-98 doi:10.1016/j.beha.2016.08.026.

Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.

Teckie S, Qi S, Chelius M, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2017; (28(5)):1064-1069 doi:10.1093/annonc/mdx025.

Analysis of Clinical Characteristics for 24 Cases of Nodal Marginal Zone Lymphoma.

Lü R, Yi S, Li Z, et al.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2017; (39(2)):236-239 doi:10.3881/j.issn.1000-503X.2017.02.012.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, et al.

British journal of haematology 2017; (179(3)):439-448 doi:10.1111/bjh.14881.

Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.

Thieblemont C

Hematology. American Society of Hematology. Education Program 2017; (2017(1)):371-378 doi:10.1182/asheducation-2017.1.371.

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Pillonel V, Juskevicius D, Ng CKY, et al.

Leukemia 2018; (32(11)):2412-2426 doi:10.1038/s41375-018-0082-4.

Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.

Cheah CY, Opat S, Trotman J, Marlton P

Internal medicine journal 2019; (49(9)):1070-1080 doi:10.1111/imj.14268.

Splenic Marginal Zone B-Cell Lymphoma With Splenic Infarction in a Patient With Cold Agglutinin Disease.

Nakamoto R, Okuyama C, Utsumi T, Yamamoto Y

Clinical nuclear medicine 2019; (44(5)):e372-e374 doi:10.1097/RLU.0000000000002528.

Monocytoid B cell lymphoma: A case report and evaluation.

Manchanda AS, Narang RS, Kaur H

Journal of oral and maxillofacial pathology : JOMFP 2019; (23(Suppl 1)):2-6 doi:10.4103/jomfp.JOMFP_101_17.

[Paediatric nodal marginal zone lymphoma: a clinicopathological study of seven cases].

Bai DY, Xie JL, Zheng YY, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology 2019; (48(5)):369-372 doi:10.3760/cma.j.issn.0529-5807.2019.05.007.

[Transformation of CD5-positive nodal marginal zone lymphoma to diffuse large B-cell lymphoma].

Koike T, Iriyama N, Nakagawa M, et al.

[Rinsho ketsueki] The Japanese journal of clinical hematology 2020; (61(3)):245-250 doi:10.11406/rinketsu.61.245.

Bilateral Primary Marginal Zone Lymphoma of the Breast - A Rare Breast Malignancy.

Talluri S, Subramanian CR, Werner E, et al.

In vivo (Athens, Greece) 2020; (34(6)):3597-3600 doi:10.21873/invivo.12204.

Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.

Shekhar R, Naseem S, Binota J, et al.

Hematology/oncology and stem cell therapy 2021; (14(3)):231-239 doi:10.1016/j.hemonc.2020.10.003.

Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.

Knauf W, Abenhardt W, Koenigsmann M, et al.

Hematological oncology 2021; (39(3)):313-325 doi:10.1002/hon.2868.

Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Vela V, Juskevicius D, Dirnhofer S, et al.

Virchows Archiv : an international journal of pathology 2022; (480(2)):403-413 doi:10.1007/s00428-021-03186-3.

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Opat S, Tedeschi A, Linton K, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(23)):6323-6332 doi:10.1158/1078-0432.CCR-21-1704.

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.

Tam CS, Dimopoulos M, Garcia-Sanz R, et al.

Blood advances 2022; (6(4)):1296-1308 doi:10.1182/bloodadvances.2021005621.

How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Cabeçadas J, Nava VE, Ascensao JL, Gomes da Silva M

Current oncology (Toronto, Ont.) 2021; (28(6)):4611-4633 doi:10.3390/curroncol28060390.

[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].

Wang XY, Li M, Zhao YX, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology 2022; (51(4)):301-306 doi:10.3760/cma.j.cn112151-20211220-00915.

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

Phillips T, Chan H, Tam CS, et al.

Blood advances 2022; (6(11)):3472-3479 doi:10.1182/bloodadvances.2021006083.

Current Treatments in Marginal Zone Lymphoma.

Alderuccio JP, Kahl BS

Oncology (Williston Park, N.Y.) 2022; (36(4)):206-215 doi:10.46883/2022.25920956.

CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.

Xia Y, Ge J, Sun Z, et al.

Leukemia research 2022; (117()):106840 doi:10.1016/j.leukres.2022.106840.

Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma: A case report and literature review.

Wang M, Guo Y, Dong L, Bi K

Medicine 2022; (101(17)):e29219 doi:10.1097/MD.0000000000029219.

A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.

Salmeron-Villalobos J, Egan C, Borgmann V, et al.

Blood advances 2022; (6(16)):4661-4674 doi:10.1182/bloodadvances.2022007322.

Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop.

Cook JR, Amador C, Czader M, et al.

American journal of clinical pathology 2023; doi:10.1093/ajcp/aqad034.

Retrospective characterization of nodal marginal zone lymphoma.

Stuver R, Drill E, Qualls D, et al.

Blood advances 2023; (7(17)):4838-4847 doi:10.1182/bloodadvances.2022009587.

An extremely rare tracheal tumor in coronavirus disease-2019 screening: Marginal zone lymphoma.

Beyoglu MA, Sahin FM, Albayrak A, Yekeler E

Journal of cancer research and therapeutics 2023; (19(2)):487-489 doi:10.4103/jcrt.jcrt_1645_21.

Marginal zone lymphoma: 2023 update on diagnosis and management.

Cheah CY, Seymour JF

American journal of hematology 2023; (98(10)):1645-1657 doi:10.1002/ajh.27058.

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

Opat S, Tedeschi A, Hu B, et al.

Blood advances 2023; (7(22)):6801-6811 doi:10.1182/bloodadvances.2023010668.

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.

Arcaini L, Bommier C, Alderuccio JP, et al.

EClinicalMedicine 2024; (72()):102592 doi:10.1016/j.eclinm.2024.102592.

A Rare Case of Refractory Nodal Marginal Zone Lymphoma in a Child, Successfully Cured by Allogeneic Stem Cell Transplant: A Case Report.

Memon S, Almudayfir Z, Elbashir E, et al.

Pediatric transplantation 2024; (28(6)):e14835 doi:10.1111/petr.14835.

Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.

Wang H, Zhang Y, Li Z, Bai O

Frontiers in immunology 2024; (15()):1466859 doi:10.3389/fimmu.2024.1466859.

Pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma: additional evidence to support they are a single disease with variation in the histologic spectrum.

Li HG, Jiang XN, Xue T, et al.

Virchows Archiv : an international journal of pathology 2024; (485(5)):889-900 doi:10.1007/s00428-024-03941-2.

Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

Grover NS, Annunzio K, Watkins M, et al.

Blood cancer journal 2024; (14(1)):182 doi:10.1038/s41408-024-01162-z.

18F-FDG PET or PET/CT in detecting high-grade transformation of chronic lymphocytic leukaemia and indolent lymphomas: a systematic review and meta-analysis.

Lee ONY, Kuruvilla J, Hodgson DC, et al.

The British journal of radiology 2025; (98(1169)):669-678 doi:10.1093/bjr/tqaf028.

[Update on marginal zone lymphoma classification, diagnosis and treatment in 2024].

Oberic L, Bouabdallah K, Carras S, Thieblemont C

Bulletin du cancer 2025; (112(5)):527-541 doi:10.1016/j.bulcan.2025.01.013.

Marginal B-cell lymphoma: A 10-year retrospective study at national institute of hematology and blood transfusion, Vietnam.

Vu BD, Nguyen HQ, Le CQ, et al.

SAGE open medicine 2025; (13()):20503121251334508 doi:10.1177/20503121251334508.

Nodal Marginal Zone Lymphoma with Simultaneous Transformation at Diagnosis and Pleural Effusion as the Initial Presentation: A Case Report.

Dodos K, Kalamara VT, Georgakopoulou VE, Kavoura P

Acta medica Lituanica 2025; (32(1)):210-211 doi:10.15388/Amed.2025.32.1.21.

Nodal Marginal Zone Lymphoma with Prominent Expansion of PD-1+ T-Follicular Helper Cells: A Persistent Diagnostic Challenge with a Heterogeneous Mutational Architecture.

Crisci S, De Chiara A, Oro M, et al.

International journal of molecular sciences 2025; (27(1)) doi:10.3390/ijms27010051.

IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis.

Yüksel S, Aygün RŞ, Yüksel M, et al.

Annals of hematology 2026; (105(8)).

Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases.

Dalland JC, Oyedeji OS, Viswanatha DS, et al.

Journal of hematopathology 2026; (19(1)).